Seeking Alpha

Amicus, Biogen to collaborate on Parkinson's

  • Amicus Therapeutics (FOLD) inks a collaboration deal with Biogen (BIIB) for the discovery, development, and commercialization of novel small molecules for the treatment of Parkinson's disease.
  • This is a preclinical venture. The two companies will seek to discover a new class of small molecules that target the GCase enzyme.
  • There are no upfront payments to FOLD.
  • BIIB will fund all discovery, development, and commercialization and will reimburse FOLD for the cost of employees working on the project.
  • FOLD is eligible for development and regulatory milestones and "modest" royalties. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|